Navigation Links
ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement
Date:4/11/2008

TUCSON, Ariz., April 11 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that it received a NASDAQ Staff Deficiency Letter on April 11, 2008 indicating that for the last 30 consecutive business days, the bid price of its common stock has closed below $1.00 per share. As a result, the company fails to comply with the minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4).

In accordance with Marketplace Rule 4310(c)(8)(D), the company has been provided 180 calendar days, or until October 8, 2008, to regain compliance. The company will achieve compliance, if before October 8, 2008, the bid price of the company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days. If the company does not regain compliance by October 8, 2008, but can demonstrate as of that date that the Company meets the criteria for initial listing set forth in Marketplace Rule 4310(c) (other than the bid price requirement) and its application is approved, the Company will have an additional 180 days to regain compliance.

The Company intends to monitor the closing bid price of its common stock between now and October 8, 2008, and work closely with NASDAQ to resolve the deficiency and consider available options to regain compliance with the NASDAQ minimum closing bid price requirement.

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its product, urokinase for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
2. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
3. ImaRx to Report Corporate Updates and 4Q07 Financial Results
4. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
5. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
6. Stemline Therapeutics Raises $12.5 Million
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Amsterdam Molecular Therapeutics Part of Next Biotech Index
9. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
10. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
11. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... According to the International Atomic Energy Agency (IAEA) ... terrorists acquiring sufficient quantities of plutonium or highly ... explosive device. The IAEA also notes that most ... quantities, which can be challenging to detect with ... study appearing this week in the Journal ...
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
(Date:7/10/2014)... Wash. The lithium-ion batteries that power our laptops ... longer on a single charge with the help of ... porous material to replace the graphite traditionally used in ... than 10 times the energy storage capacity of graphite. ... battery electrode was published today in Nature Communications ...
(Date:7/10/2014)... recent study by researchers at the University of ... physical mechanisms governing the interplay of spin and ... limits of ultrafast spintronic devices for data storage ... charge as well as spin-angular momentum. In a ... there is no spin current," explained David Cahill, ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3University of Illinois study advances limits for ultrafast nano-devices 2
... ... stick that can be shipped from stock greatly minimizing lead times for Semiconductor tool ... (PRWEB) ... specializing in process controls for the delivery of critical fluids, introduces an innovation to ...
... , PLEASANTON, Calif., FRAMINGHAM, Mass. ... THOR ), a world leader in device-based mechanical circulatory support ... International, Inc. (Nasdaq: HTWR ; ASX: HIN), which ... the United States Federal Trade Commission ("FTC") has informed them ...
... , , BETHESDA, Md., July ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation ... of its common stock in a public offering. Piper Jaffray & ... Capital Markets as co-manager in this offering. The offering is ...
Cached Biology Technology:Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up 2Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up 3U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 2U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 3U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 4Micromet Announces Public Offering of Common Stock 2Micromet Announces Public Offering of Common Stock 3Micromet Announces Public Offering of Common Stock 4
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... , July 11, 2014 Research and ... "International Biometrics Technology Market - Industry Analysis Size Share ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... crimes has created a need for high level security ... for personnel authentication such as username and passwords, tokens ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute ... in skin keratinocytes is important for formation and maintenance ... reported in the Journal of Biological Chemistry. ... namely "thermoTRPs". It is expressed in skin, acting as ...
... -- Astronauts are known to have a higher risk of ... go with weightlessness, confined crew quarters, being away from family ... while not getting enough sleep - are known to wreak ... by immunobiologist Ty Lebsack at the University of Arizona has ...
... same digital technology that enables young people to play video ... a simulated coral reef environment where they participate in science ... Field Museum scientists will link students from Chicago,s Austin neighborhood ... the Pacific Ocean, engage in the scientific process, and participate ...
Cached Biology News:Immune system compromised during spaceflight, study finds 2Immune system compromised during spaceflight, study finds 3Field Museum technology project wins prestigious award 2
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
biotin-4-fluorescein...
... Consists of the LVF-HL, LVF-CUVADPT, FHS-LVF, and ... high-pass and low-pass Linear Variable Filters to ... an adjustable center wavelength and adjustable bandpass. ... (~90%) and blocking band (99.8%). These ...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: